Strategy Pref A 10.00%'s 15min chart triggers KDJ Golden Cross, Bullish Marubozu

The 15-minute chart for Strategy Pref A 10.00% triggered a KDJ Golden Cross and Bullish Marubozu on October 21, 2025, at 15:30. This indicates a shift in the momentum of the stock price towards the upside, with a potential for further increase. The buyers currently hold control of the market, and it is likely that the bullish momentum will continue.

Talphera Inc. (TLPH) stock experienced a notable shift in momentum on October 21, 2025, as indicated by a KDJ Golden Cross and Bullish Marubozu on the 15-minute chart. This technical signal suggests a potential for further upward movement in the stock price, with buyers currently controlling the market. This bullish momentum could be sustained, making it an attractive opportunity for investors.

In addition to the technical indicators, Talphera has made several significant announcements recently. On September 8, 2025, the company announced a private placement financing of up to $29 million, led by CorMedix Inc. and other institutional investors. This funding is expected to support Talphera's planned Niyad PMA approval in H2 2026 . The company also reached a milestone in its NEPHRO CRRT pivotal trial, enrolling 17 patients, which represents approximately 25% of the targeted 70-patient enrollment .

Further financial updates were provided in the second quarter of 2025. Talphera reported a net loss of $3.5 million ($0.10 per share), a decrease from the previous year's loss of $3.8 million. Operating expenses were also reduced to $3.7 million from $4.3 million year-over-year . The company's cash position stood at $6.8 million as of June 30, 2025, and it secured a three-tranche financing of up to $14.8 million .

Additionally, Talphera announced the appointment of Joe Todisco to its Board of Directors on October 21, 2025 Talphera Inc Stock Price, News & Analysis^[1]. This strategic move is likely to bring valuable expertise and guidance to the company's leadership, further enhancing its development and regulatory strategies.

Investors and financial professionals should closely monitor Talphera's progress in its clinical trials and financial developments to gauge the potential for continued stock price appreciation. The company's focus on innovative therapies for critical care environments and its strategic partnerships position it favorably for future growth.